[go: up one dir, main page]

IL298561B2 - Methanol-based extraction of psychoactive compounds from fungus - Google Patents

Methanol-based extraction of psychoactive compounds from fungus

Info

Publication number
IL298561B2
IL298561B2 IL298561A IL29856122A IL298561B2 IL 298561 B2 IL298561 B2 IL 298561B2 IL 298561 A IL298561 A IL 298561A IL 29856122 A IL29856122 A IL 29856122A IL 298561 B2 IL298561 B2 IL 298561B2
Authority
IL
Israel
Prior art keywords
fungus
methanol
based extraction
psychoactive compounds
psychoactive
Prior art date
Application number
IL298561A
Other languages
Hebrew (he)
Other versions
IL298561B1 (en
IL298561A (en
Original Assignee
Psilo Scientific Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA3088384A external-priority patent/CA3088384C/en
Priority claimed from CA3097246A external-priority patent/CA3097246C/en
Priority claimed from CA3101765A external-priority patent/CA3101765A1/en
Priority claimed from CA3103707A external-priority patent/CA3103707C/en
Application filed by Psilo Scientific Ltd filed Critical Psilo Scientific Ltd
Priority claimed from PCT/CA2021/050813 external-priority patent/WO2021253116A1/en
Publication of IL298561A publication Critical patent/IL298561A/en
Publication of IL298561B1 publication Critical patent/IL298561B1/en
Publication of IL298561B2 publication Critical patent/IL298561B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A61K36/078—Psilocybe
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D11/00—Solvent extraction
    • B01D11/02—Solvent extraction of solids
    • B01D11/0215—Solid material in other stationary receptacles
    • B01D11/0253—Fluidised bed of solid materials
    • B01D11/0257—Fluidised bed of solid materials using mixing mechanisms, e.g. stirrers, jets
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D11/00—Solvent extraction
    • B01D11/02—Solvent extraction of solids
    • B01D11/028—Flow sheets
    • B01D11/0284—Multistage extraction
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D11/00—Solvent extraction
    • B01D11/02—Solvent extraction of solids
    • B01D11/0288—Applications, solvents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D11/00—Solvent extraction
    • B01D11/02—Solvent extraction of solids
    • B01D11/0292—Treatment of the solvent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
IL298561A 2020-06-17 2021-06-14 Methanol-based extraction of psychoactive compounds from fungus IL298561B2 (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US202063040317P 2020-06-17 2020-06-17
US202063046089P 2020-06-30 2020-06-30
CA3088384A CA3088384C (en) 2020-06-17 2020-07-29 Extraction of psychoactive compounds from psilocybin fungus
CA3089455A CA3089455C (en) 2020-06-17 2020-08-07 Methanol-based extraction of psychoactive compounds from fungus
CA3097246A CA3097246C (en) 2020-10-23 2020-10-23 Process for obtaining a purified psychoactive alkaloid solution
CA3101765A CA3101765A1 (en) 2020-12-04 2020-12-04 Psychoactive alkaloid extraction and composition with controlled dephosphorylation
CA3103707A CA3103707C (en) 2020-12-18 2020-12-18 Standardized psychoactive alkaloid extract composition
PCT/CA2021/050813 WO2021253116A1 (en) 2020-06-17 2021-06-14 Compositions comprising psychoactive compounds from psychoactive organisms

Publications (3)

Publication Number Publication Date
IL298561A IL298561A (en) 2023-01-01
IL298561B1 IL298561B1 (en) 2025-06-01
IL298561B2 true IL298561B2 (en) 2025-10-01

Family

ID=79022851

Family Applications (9)

Application Number Title Priority Date Filing Date
IL305632A IL305632B2 (en) 2020-06-17 2021-06-14 Extraction of psychoactive compounds from psychedelic mushrooms
IL298561A IL298561B2 (en) 2020-06-17 2021-06-14 Methanol-based extraction of psychoactive compounds from fungus
IL299450A IL299450A (en) 2020-06-17 2021-06-14 Dephosphorylation-controlled extraction of phosphorylatable psychoactive alkaloids
IL299451A IL299451B2 (en) 2020-06-17 2021-06-14 Extraction of psychoactive alkaloid is mainly carried out using alkali
IL299452A IL299452B2 (en) 2020-06-17 2021-06-14 Psychoactive alkaloid extraction and composition with controlled dephosphorylation
IL299453A IL299453B2 (en) 2020-06-17 2021-06-14 Extraction and synthesis of psychoactive alkaloids with inhibited dephosphorylation
IL297791A IL297791B2 (en) 2020-06-17 2022-10-30 Extraction of psychoactive compounds from psychedelic fungus
IL299448A IL299448B2 (en) 2020-06-17 2022-12-25 Process for obtaining a purified psychoactive alkaloid solution
IL299449A IL299449B2 (en) 2020-06-17 2022-12-25 Standardized psychoactive alkaloid extract composition

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL305632A IL305632B2 (en) 2020-06-17 2021-06-14 Extraction of psychoactive compounds from psychedelic mushrooms

Family Applications After (7)

Application Number Title Priority Date Filing Date
IL299450A IL299450A (en) 2020-06-17 2021-06-14 Dephosphorylation-controlled extraction of phosphorylatable psychoactive alkaloids
IL299451A IL299451B2 (en) 2020-06-17 2021-06-14 Extraction of psychoactive alkaloid is mainly carried out using alkali
IL299452A IL299452B2 (en) 2020-06-17 2021-06-14 Psychoactive alkaloid extraction and composition with controlled dephosphorylation
IL299453A IL299453B2 (en) 2020-06-17 2021-06-14 Extraction and synthesis of psychoactive alkaloids with inhibited dephosphorylation
IL297791A IL297791B2 (en) 2020-06-17 2022-10-30 Extraction of psychoactive compounds from psychedelic fungus
IL299448A IL299448B2 (en) 2020-06-17 2022-12-25 Process for obtaining a purified psychoactive alkaloid solution
IL299449A IL299449B2 (en) 2020-06-17 2022-12-25 Standardized psychoactive alkaloid extract composition

Country Status (6)

Country Link
US (4) US11331357B2 (en)
EP (1) EP4161546A4 (en)
AU (7) AU2021290454B2 (en)
BR (1) BR112022025780A2 (en)
IL (9) IL305632B2 (en)
MX (1) MX2022016533A (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020358720A1 (en) 2019-10-01 2022-04-21 Empyrean Neuroscience, Inc. Genetic engineering of fungi to modulate tryptamine expression
CA3113240C (en) 2020-12-28 2023-09-05 Psilo Scientific Ltd. Transmucosal psychoactive alkaloid composition and preparation thereof
US20220370413A1 (en) 2021-03-06 2022-11-24 Mind Medicine, Inc. Formulations of psilocin that have enhanced stability
CA3127180C (en) * 2021-08-06 2024-03-05 Psilo Scientific Ltd. Pre-evaporation standardization of extracted psychoactive compounds
CA3133547C (en) * 2021-10-07 2024-07-02 Psilo Scientific Ltd LIQUID-LIQUID EXTRACTION OF PURIFIED PSYCHOACTIVE ALKALOIDS
WO2023130078A2 (en) 2021-12-31 2023-07-06 Empyrean Neuroscience, Inc. Genetically modified mycelium for producing psychotropic alkaloids
WO2023225186A1 (en) * 2022-05-18 2023-11-23 Chemtor, Lp Extraction of psilocybin and psilocin
GB202313750D0 (en) 2023-09-08 2023-10-25 Psyence Group Inc A process for obtaining a purified psychoactive alkaloid
WO2025087962A1 (en) 2023-10-23 2025-05-01 Reconnect Labs Ag Pharmaceutical formulations comprising 5-meo-dmt and their therapeutic uses

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB911946A (en) * 1958-02-21 1962-12-05 Sandoz Ltd Psilocybin and psilocin and processes for their preparation
CN101292727A (en) * 2008-05-30 2008-10-29 曹晋忠 Powder preparing method for mushroom ethyl alcohol extract

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE264023C (en)
LU36879A1 (en) 1958-02-21
DD264023A1 (en) * 1987-07-17 1989-01-18 Akad Wissenschaften Ddr PROCESS FOR EXTRACTION OF INDOLALCALOIDS FROM MUSHROOM MATERIAL
US6596298B2 (en) 1998-09-25 2003-07-22 Warner-Lambert Company Fast dissolving orally comsumable films
IL163759A0 (en) 2002-02-28 2005-12-18 Mallinckrodt Inc Method and system for separation and purification of at least one narcotic alkaloid using reverse phase preparative chromatography
SE0302947D0 (en) 2003-01-24 2003-11-07 Magle Ab A composition material for transmucosal delivery
WO2008033024A2 (en) 2006-09-15 2008-03-20 Echo Pharmaceuticals B.V. Dosage unit for sublingual, buccal or oral administration of water-insoluble pharmaceutically active substances
AU2011235597B2 (en) 2010-03-30 2015-07-16 Phosphagenics Limited Transdermal delivery patch
CN106573123B (en) 2014-06-30 2021-08-31 Syqe医药有限公司 Methods, devices and systems for pulmonary delivery of active agents
US20180021326A1 (en) 2016-07-23 2018-01-25 Paul Edward Stamets Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin
NL2018190B1 (en) 2017-01-18 2018-07-26 Procare Beheer B V Psilocybin or psilocin in combination with cannabinoid
BR112019016489A2 (en) 2017-02-09 2020-04-07 Caamtech Llc compositions and methods comprising a psilocybin derivative
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
WO2019099745A1 (en) * 2017-11-16 2019-05-23 CaaMTech, LLC Compositions comprising a psilocybin derivative and a cannabinoid
CN109528846A (en) * 2018-12-27 2019-03-29 贵州理工学院 A kind of method of Alkaloids in Plants extraction purification
WO2020181194A1 (en) 2019-03-07 2020-09-10 University Of Padova Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations
WO2020219656A1 (en) 2019-04-26 2020-10-29 The University Of North Carolina At Chapel Hill Methods and compositions for dual glycan binding aav2.5 vector
CA3097246C (en) 2020-10-23 2023-03-28 Psilo Scientific Ltd. Process for obtaining a purified psychoactive alkaloid solution
CA3088384C (en) 2020-06-17 2021-08-03 Psilo Scientific Ltd. Extraction of psychoactive compounds from psilocybin fungus
WO2021003467A1 (en) 2019-07-04 2021-01-07 Sw Holdings, Inc. Metered dosing compositions and methods of use of psychedelic compounds
US11208117B2 (en) 2019-07-09 2021-12-28 Refraction Ai, Inc. Method and system for autonomous vehicle control
WO2021159213A1 (en) * 2020-02-12 2021-08-19 Neonmind Biosciences Inc. Method for producing an extract of mushroom and mushroom extract made therefrom
US11382942B2 (en) 2020-06-17 2022-07-12 Psilo Scientific Ltd. Extraction of psychoactive compounds from psilocybin fungus
US20220054402A1 (en) 2020-11-05 2022-02-24 Richard C Kaufman Compositions and methods for extracting, stabilizing, and manufacturing stable dosage forms of psilocin, psychedelic drugs, entheogens, and medicinal mushrooms as nano-dimensional drug delivery structures
WO2022221554A2 (en) 2021-04-16 2022-10-20 Callitas Health Inc. Compositions and methods for delivery of psilocin and prodrugs thereof
US12440472B2 (en) 2021-06-16 2025-10-14 Intelgenx Corp. Stable tryptamine oral films

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB911946A (en) * 1958-02-21 1962-12-05 Sandoz Ltd Psilocybin and psilocin and processes for their preparation
CN101292727A (en) * 2008-05-30 2008-10-29 曹晋忠 Powder preparing method for mushroom ethyl alcohol extract

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
ANASTOS, NICOLE, ET AL., THE DETERMINATION OF PSILOCIN AND PSILOCYBIN IN HALLUCINOGENIC MUSHROOMS BY HPLC UTILIZING A DUAL REAGENT ACIDIC POTASSIUM PERMANGANATE AND TRIS (2, 2??BIPYRIDYL) RUTHENIUM (II) CHEMILUMINESCENCE DETECTION SYSTEM., 31 December 2006 (2006-12-31) *
AUSTRALIAN GOVERNMENT, DEPARTMENT OF HEALTH AND AGEING, GUIDANCE ON EQUIVALENCE OF HERBAL EXTRACTS IN COMPLEMENTARY MEDICINES., 28 February 2011 (2011-02-28) *
BEUG 1980MICHAEL, W. B., AND B. JEREMY., QUANTITATIVE ANALYSIS OF PSILOCYBIN AND PSILO-CIN IN PSILOCYBE BAEOEYSTIS BY HPLC AND TLC., 31 December 1981 (1981-12-31) *
FRICKE, JANIS, ET AL., PRODUCTION OPTIONS FOR PSILOCYBIN: MAKING OF THE MAGIC., 31 December 2019 (2019-12-31) *
GARTZ, JOCHEN., EXTRACTION AND ANALYSIS OF INDOLE DERIVATIVES FROM FUNGAL BIOMASS., 31 December 1994 (1994-12-31) *
KUNLE, STANDARDIZATION OF HERBAL MEDICINES, 31 March 2012 (2012-03-31) *
KYSILKA, ROMAN, AND MILAN WURST., A NOVEL EXTRACTION PROCEDURE FOR PSILOCYBIN AND PSILOCIN DETERMINATION IN MUSHROOM SAMPLES., 31 December 1990 (1990-12-31) *
MAHMOOD, ZAFAR ALAM., BIOACTIVE ALKALOIDS FROM FUNGI: PSILOCYBIN 18., 31 December 2013 (2013-12-31) *
PELLEGRINI, MANUELA, ET AL., MAGIC TRUFFLES OR PHILOSOPHER'S STONES: A LEGAL WAY TO SELL PSILOCYBIN?., 31 December 2013 (2013-12-31) *
PERKAL, M., ET AL., DETERMINATION OF HALLUCINOGENIC COMPONENTS OF PSILOCYBE MUSHROOMS USING HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY., 31 December 1980 (1980-12-31) *
RAYMOND C. VAN ORDEN, VAN ORDEN, 31 December 2008 (2008-12-31) *
TSUJIKAWA, KENJI, ET AL., MORPHOLOGICAL AND CHEMICAL ANALYSIS OF MAGIC MUSHROOMS IN JAPAN., 31 December 2003 (2003-12-31) *
WIECZOREK, PIOTR PAWE?, ET AL., BIOACTIVE ALKALOIDS OF HALLUCINOGENIC MUSHROOMS., 31 December 2015 (2015-12-31) *
WURST, MILAN, ROMAN KYSILKA, AND TOMAS KOZA., ANALYSIS AND ISOLATION OF INDOLE ALKALOIDS OF FUNGI BY HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY., 31 December 1992 (1992-12-31) *
ZHUK, OLGA, ET AL., RESEARCH ON ACUTE TOXICITY AND THE BEHAVIORAL EFFECTS OF METHANOLIC EXTRACT FROM PSILOCYBIN MUSHROOMS AND PSILOCIN IN MICE., 31 December 2015 (2015-12-31) *

Also Published As

Publication number Publication date
IL299452A (en) 2023-02-01
AU2022291413A1 (en) 2023-02-02
AU2022291413B2 (en) 2024-02-22
IL299451B1 (en) 2024-08-01
IL298561B1 (en) 2025-06-01
IL299453A (en) 2023-02-01
US11298388B2 (en) 2022-04-12
US11642385B2 (en) 2023-05-09
IL299449B2 (en) 2025-11-01
IL305632B1 (en) 2025-04-01
IL299451A (en) 2023-02-01
AU2022291410B2 (en) 2024-04-04
US20220226405A1 (en) 2022-07-21
AU2022291414B2 (en) 2023-12-07
AU2021290454A1 (en) 2023-01-19
AU2023285751A1 (en) 2024-01-18
EP4161546A1 (en) 2023-04-12
US11571450B2 (en) 2023-02-07
IL299450A (en) 2023-02-01
AU2022291411A1 (en) 2023-02-02
AU2022291416A1 (en) 2023-02-02
EP4161546A4 (en) 2024-10-09
BR112022025780A2 (en) 2023-01-10
IL297791B1 (en) 2025-06-01
AU2022291410A1 (en) 2023-02-02
AU2023285751B2 (en) 2024-06-06
IL299449B1 (en) 2025-07-01
IL299448B1 (en) 2025-07-01
US20210393716A1 (en) 2021-12-23
IL299448B2 (en) 2025-11-01
IL305632B2 (en) 2025-08-01
MX2022016533A (en) 2023-04-05
IL298561A (en) 2023-01-01
IL299448A (en) 2023-02-01
IL297791B2 (en) 2025-10-01
AU2022291414A1 (en) 2023-02-02
IL299452B1 (en) 2024-09-01
US20220202886A1 (en) 2022-06-30
IL299449A (en) 2023-02-01
US20220040246A1 (en) 2022-02-10
IL299451B2 (en) 2024-12-01
AU2022291411B2 (en) 2023-12-07
AU2021290454B2 (en) 2024-01-11
AU2022291416B2 (en) 2024-03-28
IL305632A (en) 2023-11-01
IL299453B1 (en) 2024-08-01
IL299452B2 (en) 2025-01-01
US11331357B2 (en) 2022-05-17
IL299453B2 (en) 2024-12-01
IL297791A (en) 2022-12-01

Similar Documents

Publication Publication Date Title
IL298561B2 (en) Methanol-based extraction of psychoactive compounds from fungus
SG10201811384TA (en) Mnk inhibitors and methods related thereto
AU2015293541B2 (en) Substituted phenyl alkanoic acid compounds as GPR120 agonists and uses thereof
PH12017501888A1 (en) Bromodomain inhibitor
NI201700020A (en) AMINOPYRIMIDINYL COMPOUNDS AS JAK INHIBITORS
CA2895256C (en) Process for the preparation of substituted oxiranes and triazoles
HK1252685A1 (en) Jak kinase inhibitor compounds for treatment of respiratory disease
PH12018500591B1 (en) Heterocyclic compounds and uses thereof
PH12017502082A1 (en) Antifungal compounds
MX2018001990A (en) Compositions comprising a pi3k inhibitor and an hdac inhibitor.
UY35353A (en) AN MDM2 INHIBITOR DERIVED FROM BENZOIC ACID FOR CANCER TREATMENT
MX2017010195A (en) SALT FROM A PYRIMID COMPOUND [6,1-A] ISOQUINOLIN-4-ONA.
NZ732909A (en) 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as adamts inhibitors for the treatment of osteoarthritis
MX2020010839A (en) Aripiprazole formulations having increased injection speeds.
NZ724890A (en) Tetrazolone-substituted dihydropyridinone mgat2 inhibitors
MY194116A (en) Pharmaceutical compounds
IL261196A (en) Pharmaceutical composition for treatment of cancer, containing polyphenol compound as active ingredient
MX2018008507A (en) Inhibiting ataxia telangiectasia and rad3-related protein (atr).
MX2016013431A (en) Pharmaceutical compositions comprising antibacterial agents.
AR105821A1 (en) USEFUL COMPOUNDS TO INHIBIT ROR-g-T
MY193239A (en) Novel b-lactamase inhibitors
EP3632456A4 (en) PHARMACEUTICAL COMPOSITION CONTAINING EXTRACT OF <i /> VACCINIUM BRACTEATUM SHEETS
IN2014MU00859A (en)
EP4387615A4 (en) Liquid-liquid extraction of purified psychoactive alkaloid
EP4366751A4 (en) Pre-evaporation standardization of extracted psychoactive compounds